midpage
Projects
Sign in to see your projects.
318 F. Supp. 3d 321
D.C. Cir.
2018
Read the full case

Background

  • Alcresta Therapeutics and patient Jonathan Flath sued HHS challenging the agency's denial/refusal to grant a new permanent billing code for Relizorb; they sought a preliminary injunction and later appealed the denial.
  • The court denied the preliminary injunction, finding Plaintiffs failed to show irreparable harm and that Flath likely lacked standing; Plaintiffs then filed an Emergency Motion for an injunction pending appeal.
  • Plaintiffs sought (a) enforcement of FACA/procedural compliance in considering Alcresta’s 2018 application, (b) a reasoned decision on the 2017 application, and (c) a temporary, usable billing code for Relizorb.
  • The government opposed the emergency motion and submitted an unrebutted declaration that code B4035 remains a valid Medicare billing code allowing claims and appeals processing.
  • The court applied the standard for an injunction pending appeal (substantially the same as for a preliminary injunction) and concluded Plaintiffs failed to show a likelihood of irreparable harm, so the emergency motion was denied.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Standard: sliding-scale vs. Winter test Sliding-scale should apply; strong merits could offset weaker irreparable-harm showing Winter controls; movant must show likely irreparable harm; sliding-scale is doubtful post-Winter Court: Winter requires likely irreparable harm; need not analyze other factors when irreparable harm lacking
Irreparable harm — patient access (Flath) Flath argues inability to obtain Relizorb/Medicare reimbursement causes irreparable health/financial harm Changing billing code will not compel government insurers to reimburse; B4035 remains valid for claims and appeals Court: No irreparable harm—injunctive relief sought would not remedy alleged injury; also found standing problems for Flath
Irreparable harm — Alcresta lost profits Alcresta claims $15M in lost, unrecoverable profits; argues monetary loss justifies injunction pending appeal Lost profits not shown to be certain, great, and imminent; financial context missing; unrecoverable money alone insufficient Court: Monetary losses not shown to be irreparable; plaintiffs failed to prove magnitude/certainty required
Procedural injury (FACA) Government’s alleged FACA violation causes procedural injury warranting injunction Procedural violation alone, without great concrete harm, does not justify injunction; plaintiffs did not show added harm Court: Procedural FACA claim does not supply irreparable harm absent concrete, great injury; denial affirmed

Key Cases Cited

  • Winter v. Natural Resources Defense Council, 555 U.S. 7 (2008) (plaintiff must demonstrate irreparable injury is likely to obtain preliminary relief)
  • Chaplaincy of Full Gospel Churches v. England, 454 F.3d 290 (D.C. Cir. 2006) (failure to show irreparable harm alone supports denial of preliminary injunction)
  • FTC v. Weyerhaeuser Co., 648 F.2d 739 (D.C. Cir. 1981) (failure to show irreparable harm warrants denial of injunction pending appeal)
  • Nken v. Holder, 556 U.S. 418 (2009) (standards for stays and consideration of harms in appellate context)
  • Davis v. Pension Benefit Guar. Corp., 571 F.3d 1288 (D.C. Cir. 2009) (discusses sliding-scale approach and post-Winter analysis)
  • Sherley v. Sebelius, 644 F.3d 388 (D.C. Cir. 2011) (historical sliding-scale precedent discussed)
  • Cardinal Health, Inc. v. Holder, 846 F. Supp. 2d 203 (D.D.C. 2012) (economic losses do not automatically establish irreparable harm; must be great, certain, imminent)
  • Ohio Oil Co. v. Conway, 279 U.S. 813 (1929) (historical authority on certain and irreparable monetary injury)
Read the full case

Case Details

Case Name: Alcresta Therapeutics, Inc. v. Azar
Court Name: Court of Appeals for the D.C. Circuit
Date Published: Jun 28, 2018
Citations: 318 F. Supp. 3d 321; Civil Action No. 18–243 (TJK)
Docket Number: Civil Action No. 18–243 (TJK)
Court Abbreviation: D.C. Cir.
Log In
    Alcresta Therapeutics, Inc. v. Azar, 318 F. Supp. 3d 321